The Factors Affecting IPP in Peritoneal Dialysis Patients with Polycystic Kidney Disease
Launched by PEKING UNIVERSITY FIRST HOSPITAL · Feb 18, 2025
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Aged 18-80 years;
- • 2. A confirmed diagnosis of polycystic kidney disease, with a history of peritoneal dialysis catheter placement and regular peritoneal dialysis;
- • 3. Able to tolerate the infusion of more than 1500 mL of dialysis fluid.
- Exclusion Criteria:
- • 1. Acute complications such as peritonitis or cardiovascular and cerebrovascular events within the past month;
- • 2. History of abdominal surgery or trauma within the past month;
- • 3. History of kidney cyst rupture, infection, or bleeding within the past month;
- • 4. History of abdominal or pelvic organ tumors;
- • 5. History of abdominal pressure-related complications, such as hernias, leaks, or chest-abdominal fistulas;
- • 6. Unable to attend follow-up visits during the study period;
- • 7. Refusal to participate in the study. -
About Peking University First Hospital
Peking University First Hospital is a leading medical institution in China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its extensive expertise in various medical fields to conduct rigorous studies aimed at improving patient outcomes and contributing to global medical knowledge. With a multidisciplinary team of skilled researchers and clinicians, Peking University First Hospital is dedicated to the ethical conduct of clinical research, ensuring the highest standards of safety and efficacy in its trials. The institution plays a vital role in translating scientific discoveries into effective treatments, thereby enhancing the quality of care for patients both locally and worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported